ZYBERNO
Stock Report
Updated Sep 1, 2026

AIM IMMUNOTECH INC. (AIM)

Healthcare • NYSE

$0.24

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
AIM IMMUNOTECH INC. (AIM) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-184.3%)
Debt-to-Equity (Solvency Risk):GOOD (0.56x)
Operating Margin (Operational Efficiency):CRITICAL (-11,724.2%)
Return on Capital (Capital Efficiency):CRITICAL (-164.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

AIM IMMUNOTECH INC. (AIM) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, AIM generated -$13.82M in Owner Earnings. Reinvestment rate: 1.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.24
Market Cap:$4.04M

Valuation Multiples (3)

P/B Ratio:0.52x
P/S Ratio:42.49x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.38M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-175.1%
Reinvestment Rate:1.9%
Fundamental Growth Rate (g):-3.1%

Margin Analysis (3)

Operating Margin Ttm:-11,724.2%
Net Margin Ttm:-15,021.1%
Ebitda Margin:-11,197.9%

TTM Performance (2)

Operating Margin Ttm:-11,724.2%
Net Margin Ttm:-15,021.1%

Yield Metrics (2)

Earnings Yield:-$2.73K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:89.6%
Latest Earnings Filed:2026-08-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-18.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.11x
Quick Ratio:2.11x
Cash Ratio:2.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.56x
Debt-to-Equity Ratio:0.56x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-10.25x
Times Interest Earned:-10.25

Capital Structure (4)

Working Capital:5,486,000.00
Cash And Cash Equivalents:9,900,000.00
Long Term Debt:$3.62M
Net Debt:-$2.66M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $95.00K
Linear Growth: -18.2%
📊 Click to view full AIM Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$11.14M

Bottom Line Performance (3)

-$14.27M
Income Before Tax:-$13.96M
Ebitda Ttm:-10,638,000.00

Operating Expenses (5)

Operating Expenses:11,233,000.00
R And D Expense:2,741,000.00
Sga Expense:8,375,000.00
Income Tax Expense:$0.00
Interest Expense:1,138,000.00

Expense Ratios (3)

R And D To Revenue Percentage:10,542.3%
Sga To Revenue Percentage:32,211.5%
Ebitda Margin:-11,197.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$12.73M
Current Assets:$10.43M
Ppe Net:54,000.00
Goodwill:0.00
Intangible Assets:$1.71M

Liability Structure (4)

Total Liabilities:4,987,000.00
Current Liabilities:4,946,000.00
Long Term Debt:$3.62M
Short Term Debt:$3.62M

Equity & Capital (3)

Equity:$7.74M
Retained Earnings:-$447.60M
Common Stock:350,000,000.00

Working Capital Items (3)

Accounts Receivable:7,000.00
Inventory:0.00
Accounts Payable:480,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.32M-$13.82M

Investment Activities (1)

Investing Cash Flow:-$37.00K

Financing Activities (3)

Financing Cash Flow:$5.59M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,001,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:500,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-6.01
-$6.01
Earnings Per Share Ttm:-$0.83

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.64

Book Value & Capital (2)

Book Value Per Share:$0.45
Cash Per Share:0.58

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.02x

Receivables Management (2)

Receivables Turnover Ttm:13.57x
Days Sales Outstanding Ttm:26.89

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:1,844.21
Cash Conversion Cycle:-2,816.32
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$13.82M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.9%
Fundamental Growth Rate (g):-3.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-18.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:AIM
Company Name:AIM IMMUNOTECH INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:17.12M
Shares Outstanding Basic:17.12M
Shares Outstanding Diluted:17.12M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 18:09:35 UTC
Data Timestamp:2026-08-22T02:35:02.863191
Scroll to Top